Docon Technologies encumbers bonus shares after Thyrocare allotment

Docon Technologies Private Limited, a wholly-owned subsidiary of API Holdings Limited and a promoter of Thyrocare Technologies Limited, reported an auto-encumbrance on 64,646,464 bonus equity shares allotted by Thyrocare on December 1, 2025. This allotment was in a 2:1 ratio (two new bonus shares for every one existing share) and followed earlier disclosures made on September 24 and November 11, 2025.

The encumbrance was created against Docon's existing shareholding and pledged in favor of Catalyst Trusteeship Limited, acting as debenture trustee. This action secures the obligations of API Holdings Limited related to unsecured, unlisted, redeemable non-convertible debentures issued by API. While the number of encumbered shares has increased to 9,69,69,696, the percentage of encumbered shareholding remains unchanged at 60.93% of Thyrocare’s total paid-up equity share capital.

The encumbrance pertains to debt instruments, specifically 12,000 unlisted, unrated, secured, redeemable non-convertible debentures (Series 1 Debentures) issued by API Holdings Limited, each with a face value of INR 1,000,000. The total nominal value of these debentures is up to INR 12,000 million. The proceeds from these debentures were fully utilized for the repayment and refinancing of API Holdings Limited's debt facilities.